Navigation Links
Antibody-guided drug works against acute lymphoblastic leukemia
Date:5/23/2011

HOUSTON An antibody packaged with a potent chemotherapy drug to selectively destroy acute lymphoblastic leukemia (ALL) cells eradicated or greatly reduced the disease for 61 percent of 46 patients in a phase II study. It will be presented at the 47th annual meeting of the American Society of Clinical Oncology in Chicago June 3-7.

Patients enrolled in the trial led by investigators at The University of Texas MD Anderson Cancer Center had ALL that resisted other therapies or recurred after treatment.

"A response rate of more than 50 percent in this patient population probably makes inotuzumab ozogamicin the most active single-agent therapy ever for ALL," said Hagop Kantarjian, M.D., professor and chair of MD Anderson's Department of Leukemia and study senior investigator.

ALL is an aggressive form of leukemia in which immature white blood cells, called lymphoblasts, grow rapidly, crowding out normal blood cells.

The drug, also known as CMC-544, links an antibody that targets CD22, a protein found on the surface of more than 90 percent of ALL cells, and the cytotoxic agent calicheamicin. Once the drug connects to CD22, the ALL cell draws it inside and dies.

Response rate for other second options is 20-30 percent

Kantarjian said second-line chemotherapy combinations used for ALL typically have a complete response rate of 20-30 percent. The monoclonal antibody-based drug developed by Pfizer, Inc., also is the first of its type for ALL.

The drug is safe, said Elias Jabbour, M.D., assistant professor in MD Anderson's Department of Leukemia, who will present the study results at ASCO on Monday, June 6. Almost all side-effects were of low grade (1-2) and manageable. Drug-induced fever was the most common side effect, reaching higher grades in nine of 48 patients.

Out of 46 patients evaluable for response, nine had a complete response, 14 had complete response without full recovery of platelets, and 5 had less than 5 percent blasts in their bone marrow without blood count recovery.

Sixteen responders subsequently received a donor blood stem cell transplant, Jabbour noted.

Drug combinations

Combining inotuzumab with other chemotherapy might further improve ALL treatment, Jabbour said. MD Anderson has a phase II clinical trial under way following inotuzumab treatment with another monoclonal antibody drug, rituximab, currently used in some types of non-Hodgkin's lymphoma.

Rituximab targets the CD20 surface protein, which occurs in 50 percent of ALL cells.

In addition to combinations, the authors suggest that a shift from dosing every three weeks to weekly should be explored.

Frontline therapy for ALL is a combination chemotherapy regimen known as HyperCVAD.

The National Cancer Institute estimates that 5,330 people received an ALL diagnosis in 2010 and 1,420 died of the disease.

ALL is the most common type of childhood cancer. Combined chemotherapy regimens have raised long-term survival from 5 percent of pediatric patients in the 1960s to 85 percent today.


'/>"/>

Contact: Scott Merville
smerville@mdanderson.org
713-792-0661
University of Texas M. D. Anderson Cancer Center
Source:Eurekalert  

Related medicine news :

1. KPA and TK Carsites offer HR, OSHA and Internet Marketing Workshops at the NADA Convention and Expo 2010
2. For Some Breast Cancer Patients, Shorter Radiation Works Well
3. Swine Flu vaccination: voluntary system works
4. mHealth Alliance Works in Partnership with GSMA to Expand Discussion of Mobile Health at 2010 Mobile World Congress
5. BCS Global Launches PSVN (Public Switched Video Network), an Initiative to Provide a Framework for Inter-Connecting Business to Business Video Networks
6. Visionworks(R) Brings High Quality Eye Care & Eye Wear to Western PA
7. Dr. Alesia Wagner of U.S. HealthWorks Medical Group Re-elected to Board of Osteopathic Physicians and Surgeons of California
8. Abbott Research Group, Inc. Launches New Product - WaterWorks
9. Learn to Dance in a Day -- Beginner Workshop Launches Modern Jive in Toronto
10. Enterprise PDM Integration has Never Been Easier; Zero Wait-State Announces Leading SolidWorks Reseller GoEngineer as Master Distributor for DesignState
11. Easy to See and Use Senior Phone Works with AT&T and T-Mobile Cellular Providers
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Antibody-guided drug works against acute lymphoblastic leukemia
(Date:8/19/2017)... ... 19, 2017 , ... Yesterday, the President of the United States retracted his ... There are not two sides to hatred, bigotry, discrimination, and a white supremacy nationalist ... NPEIV stands against all forms of such hatred and discrimination in this country and ...
(Date:8/19/2017)... ... August 19, 2017 , ... Physician Partners of America ... as an interventional pain management physician. He brings a wealth of pain management ... headaches, and significant experience in spinal cord stimulation for chronic pain. , Dr. ...
(Date:8/18/2017)... ... August 19, 2017 , ... Mr. ... presided over the Amazing Thailand Health and Wellness Tourism Showcase 2017 yesterday, which ... Pakprot, Deputy Governor for Tourism Products and Business at TAT said, “Thailand has ...
(Date:8/18/2017)... ... August 18, 2017 , ... ... For Immediate Release                Contact: Julian Teixeira, August 18, 2017                    202-478-8564 / jteixeira@thenc.org ... Advice from their Fathers , Contrary to a father’s ...
(Date:8/18/2017)... ... 18, 2017 , ... Mediaplanet today announces the launch of ... and highlighting the importance of proactive eye and ear health. The campaign focuses ... innovations in hearing aid technology. , In this issue, the National Association ...
Breaking Medicine News(10 mins):
(Date:7/31/2017)... 2017  Diplomat Pharmacy, Inc. (NYSE: DPLO), has been named ... by Crain,s Detroit Business . ... by three-year revenue growth. This year,s edition measures growth from ... view the complete list, visit crainsdetroit.com/awards/fast_50/2017 .  ... triumph," said Phil Hagerman , CEO and chairman of ...
(Date:7/31/2017)... 31, 2017 7D Surgical, developer of ground breaking ... the 7D Surgical System to support its strategic sales plan ... and Virginia.  7D Surgical has entered into an ... the premier medical facilities within those markets. ... Spartan ...
(Date:7/28/2017)... , July 28, 2017 EnvoyHealth, a Diplomat company, ... a program for CleverCap LITE, a technology designed to ... to deliver innovative health technology solutions and services that ... CleverCap LITE offers medication monitoring ... bottle cover: Records ...
Breaking Medicine Technology: